Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment.
about
Customized targeted therapy in Hodgkin lymphoma: hype or hope?Pembrolizumab in classical Hodgkin's lymphomaClinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor CellsFibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients.Incomplete cytokinesis and re-fusion of small mononucleated Hodgkin cells lead to giant multinucleated Reed-Sternberg cells.Logic Learning Machine and standard supervised methods for Hodgkin's lymphoma prognosis using gene expression data and clinical variables.Genomic Instability: The Driving Force behind Refractory/Relapsing Hodgkin's Lymphoma.A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma.Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort studyEmerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Immunological deregulation in classic hodgkin lymphoma.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategiesMacrophages and dendritic cells as actors in the immune reaction of classical Hodgkin lymphomaCharacteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma.A Multi-Component Model of Hodgkin's Lymphoma.CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma.Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab VedotinExpression of Interleukin-1 and Interleukin-1 Receptors Type 1 and Type 2 in Hodgkin Lymphoma.Primary nodular lymphocyte-predominant Hodgkin lymphoma of uterine cervix mimicking leiomyomaConstitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantationGene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphomaMeta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma.Three-dimensional Telomere Signatures of Hodgkin- and Reed-Sternberg Cells at Diagnosis Identify Patients with Poor Response to Conventional ChemotherapyTargeting the tumor niche to treat cancer.Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trialEnhanced antitumor effect of combining chemotherapy with Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes in mice with EBV-related non-Hodgkin's lymphoma.Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma.Lymphotoxin network pathways shape the tumor microenvironmentThe immunological contribution of NF-κB within the tumor microenvironment: a potential protective role of zinc as an anti-tumor agent.Exposure to UV radiation and risk of Hodgkin lymphoma: a pooled analysisAnti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphomaDefining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells.Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome.Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma.Management of children with high-risk Hodgkin lymphoma.The diverse roles of IRF4 in late germinal center B-cell differentiation.Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma.
P2860
Q27002554-098F154D-D241-4CCD-A093-D7290A9E1C0EQ28079273-854B2D92-ABE1-4548-AB32-C756C3A75C7CQ28083973-53453FFB-3655-4356-8478-1BEF85703FD4Q30449589-EA48DB5F-7EE6-4ED9-ABF5-96A19EB24A54Q30560427-96F17EFF-072D-4228-A8EB-CD4E985BCA80Q31111207-37AA797D-26BF-4E01-8897-1CD5C42A6BE0Q31143601-0CBE5C86-014B-4A9C-A2A9-3E99AFDC8251Q33397302-47E4B9E7-19F4-4D7D-A775-E97029D99F5FQ33412734-DA13E0C1-8C82-4B22-B33C-E8C047CA0FADQ33633445-89098F37-78F3-4F6B-9A1C-7A30F8864250Q33704061-7D3DD3D0-5362-4B89-AD2E-F73B73E2F434Q33778391-8F9AFC50-6078-47BC-BC89-AB0EA87A62C8Q33886267-D8E2B452-0D9F-404F-B483-FB5B0D03A7DFQ34627838-BFF4185B-5589-4B2D-B494-47C4A17F874DQ34732945-09D851F8-0F72-4F43-85E9-8F97ABE1F4DDQ35128470-E48A04B0-27CF-4D2C-AF89-BE3D10097E1BQ35615085-EA27336D-82D8-4B2E-8564-F125FCF2D7B7Q35661295-C45A2408-8ED0-4246-9D3F-AAA92DE5518CQ35669134-ED52089C-0821-49F4-AABE-776728856ECBQ35788358-FD454DD8-EC39-4A98-B55F-7CF5D53D96DDQ35841766-8CF8BF27-5E40-4F36-9B43-EF21B7AB4302Q35875897-20A0797D-D9B3-4C5C-8448-86D271E77D33Q35891651-3A8B9B0D-5CF6-4452-BAF8-AD642CA97FF7Q36051184-96179102-4814-40B5-98FF-1F8B6185C69DQ36164491-10C31476-FD88-4465-8DB2-D376040B49E7Q36199852-8CA266F7-3E81-4FD6-802A-26D3AF58BC47Q36207348-DAA53F8A-246E-4BB3-BA07-8EFAFB323BE7Q36333526-845601D8-3AAA-4B60-8A10-3524F11F3A7FQ36334405-B511F0EE-CBBA-4BD6-96F9-8F93D22DD3FAQ36615084-880714CD-D4C9-4661-B3D3-1D83EEC24341Q36823937-76013404-84EC-44C0-A997-24B802102B17Q37262995-3FADA748-7531-4F39-98F2-2466C608884EQ37311256-CD474847-C265-4F35-8003-1D525E9CC457Q37427684-02A3D46F-B015-42C9-8751-6D3B7FDD6A6FQ37623812-C8E5C2F5-3212-4AA9-990F-CFD5253F4D66Q37659012-7B67FB31-41D0-4245-BE3F-629FF3C5A260Q37683382-F9D84639-01E6-407D-9FA1-F670784B81F5Q37970408-73AD8046-69D8-405D-B507-2023505781A3Q38002486-B0765205-D229-48C3-B1F1-56D91352ACE9Q38068839-4C04A19B-1A10-4A5A-90C6-50BB82CFEBBA
P2860
Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Molecular pathogenesis of Hodg ...... tance of the microenvironment.
@ast
Molecular pathogenesis of Hodg ...... tance of the microenvironment.
@en
Molecular pathogenesis of Hodg ...... tance of the microenvironment.
@nl
type
label
Molecular pathogenesis of Hodg ...... tance of the microenvironment.
@ast
Molecular pathogenesis of Hodg ...... tance of the microenvironment.
@en
Molecular pathogenesis of Hodg ...... tance of the microenvironment.
@nl
prefLabel
Molecular pathogenesis of Hodg ...... tance of the microenvironment.
@ast
Molecular pathogenesis of Hodg ...... tance of the microenvironment.
@en
Molecular pathogenesis of Hodg ...... tance of the microenvironment.
@nl
P356
P1476
Molecular pathogenesis of Hodg ...... tance of the microenvironment.
@en
P2093
Christian Steidl
P304
P356
10.1200/JCO.2010.32.8401
P407
P577
2011-04-11T00:00:00Z